Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Mitogen-activated protein kinase (MAPK) and Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways are fundamental intracellular signaling networks that mediate cellular responses to external stimuli such as cytokines, growth factors, and environmental stress (Source: NIH, StatPearls). The MAPK pathway typically functions through a three-tier kinase module (Raf-MEK-ERK) that translates extracellular signals into cellular growth, survival, and differentiation responses (Source: Nature Reviews Molecular Cell Biology). In contrast, the JAK-STAT pathway provides a direct mechanism for cytokine receptors to influence gene expression via the phosphorylation and nuclear translocation of STAT transcription factors (Source: PubMed). Both pathways are central to the pathogenesis of chronic inflammatory conditions, autoimmune diseases, and various malignancies when they become constitutively active or dysregulated (Source: Wikipedia). Consequently, numerous small-molecule inhibitors have been developed to target specific kinases within these pathways, such as JAK inhibitors for rheumatoid arthritis and MEK inhibitors for melanoma, providing significant therapeutic benefits (Source: FDA). However, because these pathways are essential for normal immune surveillance and hematopoiesis, their systemic inhibition can lead to notable safety concerns, including immunosuppression and hematologic abnormalities (Source: PubChem).
Inhibition of intracellular kinase activity (specifically Janus kinases or Mitogen-activated protein kinases) to prevent the phosphorylation of downstream substrates, thereby blocking the nuclear translocation of transcription factors and the subsequent expression of pro-inflammatory and proliferative genes.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase (MAPK) and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathways (MAPK and JAK-STAT pathways).